Hutchisonalexander9452

05). However, there are significant differences in the disease progression between the different blood types. There was a significant difference in the progression of disease between type A and type O. Among them, patients with ONFH and type A blood had the fastest progression with an average of 2.318 years, and the slowest progression was found in type O blood with an average of 5.15 years. CONCLUSIONS The ABO blood group has no correlation with the occurrence of ONFH, but the ABO blood type is closely related to the disease progression of ONFH. © 2020 The Authors. Orthopaedic Surgery published by Chinese Orthopaedic Association and John Wiley & Sons Australia, Ltd.OBJECTIVES Food and Drug Administration (FDA) approved crizotinib for advanced ROS1-rearranged (ROS1+) non-small-cell lung cancer (NSCLC) patients due to a single-arm study PROFILE 1001. However, there is no direct comparison between crizotinib and platinum-pemetrexed chemotherapy. MATERIALS AND METHODS Clinical data of advanced ROS1+NSCLC patients treated with first-line crizotinib or platinum-pemetrexed chemotherapy between August 2010 and December 2017 were analyzed. RESULTS Seventy-seven patients were eligible, including 30 (39.0%) in the crizotinib group and 47 (61.0%) in the platinum-pemetrexed chemotherapy group. The median follow-up was 28.1 months (95% confidence interval [CI] 19.2-39.0). The objective response rate (ORR) of crizotinib (86.7%, 95% CI 73.3-96.7) was higher than that of platinum-pemetrexed chemotherapy (44.7%, 95% CI 29.8-57.4, P  less then  .001). The disease control rate (DCR) was 96.7% (95% CI 90.0-100) in the crizotinib group and 85.1% (95% CI 74.5-95.7) in the chemotherapy group (e published by John Wiley & Sons Ltd.BACKGROUND Radical orchidectomy in patients who are subsequently diagnosed with benign testicular tumours represents an overtreatment due to the deleterious effects on endogenous testosterone, fertility and body image. For these reasons, the option of partial orchidectomy should be considered in certain groups of patients. Patients with bilateral tumours (synchronous or metachronous) or a solitary testis where the lesion is no greater than 30% of the volume of the testis could be considered for a partial orchidectomy. Evidence has shown that partial orchidectomy is effective for small testicular masses with excellent survival and recurrence rates. OBJECTIVES Highlight the feasibility of maintaining post-operative fertility or normal semen parameters and endocrine function following partial orchidectomy. MATERIALS AND METHODS Data for this review was obtained through a search of the PubMed database. Papers were required to be in English and focus on adult human males. RESULTS Eligible and relevant papers were assessed for data regarding fertility, semen parameters and endocrine function following partial orchidectomy for a small testicular mass (STM). CONCLUSION It is possible to preserve both fertility and endocrine function after partial orchidectomy. Although patients may still require adjuvant radiotherapy for concomitant intratubular germ cell neoplasia (ITGCN) which results in subfertility, endocrine function is still conserved. However, it is possible to postpone radiotherapy and continue with clinical surveillance for the purposes of fertility preservation. This article is protected by copyright. All rights reserved.Citrus is the most produced fruit in the world and provides important nutrients such as vitamin C. However, citrus production worldwide faces many biotic and abiotic challenges. Citrus genetic improvement through traditional breeding is a lengthy, difficult, and laborious process due to the long juvenility, nucellar embryony, sexual incompatibility, highly heterozygous nature, and male or female sterility. The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-mediated genome editing has been suggested to be a putative solution for rapid improvement of existing citrus varieties (Dutt et al., 2015). This article is protected by copyright. All rights reserved.BACKGROUND Radiation oncologists (ROs) play an important role in managing cancer pain; however, their opioid prescribing patterns remain poorly described. METHODS The 2016 Medicare Physician Compare National Downloadable and the 2016 Medicare Part D Prescriber Data files were cross-linked to identify RO-written opioid prescriptions. RESULTS Of 4,627 identified ROs, 1,360 (29.3%) wrote >10 opioid prescriptions. DTNB research buy The average number of opioid prescriptions written was significantly (P ≤ .05) associated with the following RO characteristics sex [13.1 ± 36.5 male vs 7.5 ± 16.9 female]; years since medical school graduation [4.5 ± 11.5 1-10 years vs 12.6 ± 26.0 11-24 years vs 13.3 ± 40.9 ≥25 years]; practice size [15.5 ± 44.6 size ≤10 vs 13.3 ± 25.9 size 11-49 vs 8.5 ± 12.7 size 50-99 vs 8.8 ± 26.9 size ≥100]; Medicare Physician Quality Reporting System (PQRS) participation [12.6 ± 31.8 yes vs 7.0 ± 35.4 no]; and practice location [17.4 ± 47.0 South vs 10.6 ± 29.4 Midwest vs 8.1 ± 13.9 West vs 6.9 ± 15.2 Northeast].© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.INTRODUCTION Male breast cancer is uncommon, delay in seeking medical attention often results in late presentation and poor prognosis. METHODS Retrospective review of a prospectively maintained database was performed. Patients who were still having regular follow-up were contacted for telephone interview. RESULTS In this study, 56 male breast cancer patients were treated in our center from January 1998 to December 2018, accounting for 0.88% of all breast cancers treated during the same period of time. Median age of onset was 61 years old (Range 33-95). In this study, 6 (10.7%) patients presented with distant metastasis at the time of diagnosis and received palliative systemic treatment only. And, 50 patients were surgically treated and all had mastectomy. Axillary dissection was performed in 36 (72%) patients, while sentinel node biopsy was performed in 14 (28%) patients. Median tumor size was 23 mm (2-100 mm). A Majority were diagnosed with invasive carcinoma (NOS), while 38 (67.8%) patients were node positive.